Daridorexant for People With Insomnia and Alcohol Use Disorder Study

The goal of this clinical trial is to see if a sleep medication, daridorexant (DTX), can help decrease drinking in people who have alcohol use disorder (AUD) and insomnia. The main questions it aims to answer are: * Can DTX decrease alcohol use in individuals with insomnia better than placebo? * Can DTX increase sleep time and other sleep related outcomes better than placebo? Participants will: * Take prescribed medication (DTX or Placebo based on which group they are randomized to). * Provide urine, breath, saliva, and blood samples. * Come in for bi-weekly (once every 2 weeks) in-person visits. * Answer questionnaires and surveys related to sleep, substance use, and physical/mental health. * Use an EEG headband to track brain activity at night. * Come in for 3 follow up visits one month, six months, and one year after treatment.

Inclusion Criteria: * DSM-5 diagnosis of an insomnia disorder (i.e., difficulty initiating/maintaining sleep, early morning awakening equal or greater than 3 nights a week for equal or greater than 3 months, daytime impairment, and exclusion of other causes) * Insomnia Severity Index (ISI) score equal or greater to 15 indicating the presence of moderate or severe insomnia * 4 or more standard drinks on 4 or more occasions in the past 30 days * Seeking insomnia and AUD treatment * Aged 18+ years * DSM-5 diagnosis of AUD * Ability to read and speak English * Breath Alcohol of 0.00 for informed consent * Ability to provide written informed consent * Non-lactating women of childbearing age using a reliable form of birth control with a negative serum pregnancy test at baseline Exclusion Criteria: * Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal * Receipt of any pharmacotherapy for sleep or AUD in the past 30 days * Current DSM-5 diagnosis of sever substance use disorder that is not currently being treated, other than nicotine * Suicide attempt in the last 2 years * Moderate hepatic impairment indicating an inability to receive the full dose of 50mg/day * History of narcolepsy or complex sleep behaviors with sedative-hypnotics * Any other medical (discernible by initial blood test) or psychiatric condition that our medical team determines would compromise safe participation